Skip to main content

Education/ACR/EULAR

AI in RA: the story grows along the patient pathway

Jun 02, 2023

The use of artificial intelligence to analyse large data sets using its subset component machine learning has taken centre stage recently in the management of rheumatic conditions including rheumatoid arthritis. The use of AI is now starting to cross the various stages in patient care from

Read Article
Reflections on COVID-19 and autoimmunity: post-vaccination autoimmunity is not specific to COVID-19, autoimmunity is not autoimmune disease, the large numbers may result in the perception of increased occurrence of autoimmunity, Schulze-Koops H, COVID-19, #EULAR2023 @RheumNow https://t.co/Rm9OEWrBzo
The modern day poster tour #EULAR2023: the posters & speakers come to you, broadcast through a headset (it’s almost like a silent disco, in a hall with lots of background noise). Definite innovation but at capacity, wish more people could tune in on their own devices @RheumNow https://t.co/sOXnYctsfN
A shame. Pts with #scleroderma are dying waiting for organ transplant- we should list and work them up for Tx earlier. PAH Pts May do worse @eular_org #EULAR2023 @RheumNow OP0241 https://t.co/8ZlHJmETGA
Let le introduce you to ARTHUR 🤖 A very skilled robot who scans your hands and wrists in 15 mn 🤚 Amazing to see new #AI developments that will make our lifes’ easier! #EULAR23 @ROPCA3 @JustSoren Stand M6 @RheumNow https://t.co/7PtR2CGqTt
Should we use #immunesuppression EARLY in #scleroderma to prevent #ILD? Answer from a study comparing Y vs N immune suppression- there was no difference in FVC decline. Maybe not a long enough study, ? Chanelling bias scleroderma #lung #disease OP0239 @RheumNow #EULAR2023
#ClinicalPearl Rx of #scleroderma #ILD -add another drug. MMF, then Cyclo, Rituximab, ?tocilizumab; if progressive fibrosis then #Nintedanib ?Pirfenidone Small RCT of MMF v Tacrolimus - looked the same -helpful if MMF fails, future pregnancy OP0240 @RheumNow #EULAR2023 @eular_org https://t.co/XWphyEO2JJ
An AI algorithm to predict opined related deaths UK database >1000000 pts, 1200+ opioids related deaths Risk factors: Substance used disorder Hx self harm Alcohol abuse Oxycodone Liver disease Concomitant gabapentinoids & BZD *no pictures allowed* @Rheumnow OP0269 #EULAR23 https://t.co/II96fnhqy3
Risks for #ILD #SSc lung progression. FVC decline >5% is the gold standard but there are other criteria. OP0236 #EULAR2023 @RheumNow @eular_org #scleroderma Some criteria are stricter - larger PFT changes and/or worsening symptoms or fibrosis, so depends on def’n for % def’n https://t.co/TCuX2KY64w
Very much looking forward to our joint PRP-HRP-Rheum session later today How to improve & implement apps for self management in clinical care @ElenaNikiUK @fibrofella @ProfYelizPrior We will discuss and reveal the results of a survey made for #EULAR23 @RheumNow @eular_org https://t.co/R5vTW3FeWO

EULAR 2023 – Day 2 Report

Jun 01, 2023

Day 2 at the international EULAR Congress meeting is always bigger and busier. There were sessions on JIA therapies, crystal arthritis, novel drugs for SLE and Sjogren's, early RA and preclinical RA interventions, IgG4 disease, osteoporosis and the growth and application of artificial

Read Article

Better at Predicting RA from MRI: Humans or Computers?

Jun 01, 2023

An artificial intelligence model to assess pre-RA hand MRIs has confirmed what human readers have known before: that bone marrow edema and tenosynovitis are objectively the best predictors of future RA development in patients with clinically suspect arthralgias or undifferentiated arthritis

Read Article

AOSD: Young vs. Elderly Onset

Adult onset still's disease (AOSD) is an autoinflammatory condition characterized by fevers, arthritis, and rash. It is considered an orphan disease because of its low prevalence - it is reported anywhere between 16 to 40 per ten million. Traditionally, a bimodal distribution by age has been

Read Article
Always great to have @EMA_News to come and to talk to us at #EULAR2023 Our meds are very important to us, and the more we can understand how decisions are made and RWE is collected, the better 👍 @RheumNow https://t.co/hSutraUsFD
• Erdheim-Chester disease (ECD) is associated with Langerhans cell histiocytosis (LCH) • Bone pain, xanthelasma, hairy kidney • Differential diagnoses of LCH • BRAF mutation associated with cardiac and neurological phenotype of ECD Haroche J, Papo M #EULAR2023 @RheumNow https://t.co/AzKJKp82nq
Do we use too much PNL in GCA (when not using TCZ)? Could we wean quicker? Salvarini group n=22 26w PNL weaning protocol from GiACTA, but no TCZ 10/26 in relapse free remission at 1y Much less PNL, still some steroid AEs Way of the future for some? POS0728 #EULAR2023 @RheumNow https://t.co/qeZHeCi9vq
You need to see this! Albert with a Left V1 distribution of #shingles is a ‘bot’ who interacts with #rheumatologists at #EULAR2023 ⁦@RheumNow⁩ ⁦@eular_org⁩ #artificial #intelligence https://t.co/gDwzc3NX7v
#EULAR2023 #POS0627 Researchers in Manchester identified several proteins associated with subclinical cardiovascular abnormalities on Cardiac MRI in Scleroderma using proteomics. Need validation. Could be useful for stratification and identify therapeutic targets @RheumNow https://t.co/55eNGhMu5f
#EULAR2023 #POS0618 This is cool! Researchers from Switzerland are developing new Quantitative Radiomic Risk Score (from HRCT) to stratify response to Anti-Fibrotic in #ILD. Data presented in pre-clinical study & paralleled molecular effects. Human study is in progress @RheumNow https://t.co/qAsWew4FEO
Are we going to treat hands OA with MTX? Moderate effect on VAS pain at 6 and 12 months in a small RCT vs. PBO in hands OA WITH MRI detected synovitis. Thoughts 1) Is it really OA? 2) Benefit Risk balance remains debatable @RheumNow OP0070 #EULAR23 https://t.co/WLlX48NtGT
#CPPD and #cervical involvement. Several clinical presentations A-asymptomatic deposition B-crowned dens syndrome C-retro-odontoid pseudotumor D-inflammatory discitis Good teaching points in the supplements! @RheumNow #EULAR2023 Abst#AB1859 https://t.co/LJe7Gk1oZX
#EULAR2023 #OP0007 What are the recent trends of autoimmune disease (AID)? A database study (22m) in UK showed: - 1 in 10 people had AID in the last 20yrs - socioeconomic, seasonal & regional disparities cd influence pathogenesis - CTD (SLE,pSS,SSc) tended to co-occur @RheumNow https://t.co/3DDPR2K5NC

EULAR 2023 – Day 1 Report

May 31, 2023

EULAR 2023 launched today to crowds of attendees.  The opening Plenary session and presidential address by Dr. Ian McInnes was followed by a number of overview and review sessions with but a half-day of abstracts presentations, on several therapeutic areas including osteoarthritis, JIA, COVID

Read Article

An update on JAK inhibitors and cardiovascular risks

May 31, 2023

In the last 2 years, there has been more caution and vigilance with the use of JAK inhibitors in the treatment of rheumatoid arthritis due to the risk of CV events, including MACE and VTE. The ORAL surveillance study, a post-approval safety study conducted in RA patients aged ≥50 years with ≥1

Read Article
×